BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, today announced intent to launch its Phase 2 trial of its Multimeric-001 flu vaccine in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID).
BiondVax Pharmaceuticals Ltd. Earnings and Outlook
(NIS represents for New Israel Shekels; dollars are in quotations)
Total operating expenses were NIS 3.21m ($852,000) compared with NIS 2.18m in the second quarter of last year. R&D expenses amounted to NIS 2.61m ($693,000) compared with NIS 1.61m in the second quarter of last year. Cash, cash equivalents and short and long-term marketable securities at the end of the quarter were NIS 42.02 m ($11.15m) compared with NIS 13.68m as of December 31, 2014. PR Newswire
BiondVax Pharmaceuticals Ltd. CEO’s Comments
Ron Babecoff, the CEO of BVXV, commented regarding today’s news of phase 2 trial of their flu vaccine:
“The recognition of the potential of our technology by a foremost public health authority in the United States, is a significant milestone in our clinical development program. This trial will assess our vaccines’ ability to be used as the stockpiled flu vaccine for pandemic protection. The scenario is that immediately following a flu pandemic outbreak of any strain, our vaccine could be used from day zero, saving multiple lives and limiting the wild spread of a flu pandemic. This collaboration with NIAID brings us a significant step closer to our Phase 3 clinical trial.” PR Newswire
More of the CEO’s comments on Second Quarter 2015 results released on Aug 24:
“The second quarter of 2015 was very eventful for BiondVax, culminating in a number of successes. A few weeks following our successful public offering on Nasdaq, we completed and reported successful results for our BVX-006 trial. We showed that our universal flu vaccine enhanced antibody responses to multiple flu strains when administered as a primer, and was safe and well tolerated. More than that, a few weeks later, we showed that participants who received our vaccine in our 2012 trial, presented higher immunogenicity to the 2014-15 flu season strain – a strain which didn’t exist back then. Both these successful results are additional important data points, validating our work and further demonstrating the universality of our vaccine and its potential for improving global public health. Our work is particularly poignant as the 2015/2016 flu season approaches.”
“In terms of our efforts to broaden our shareholder base, I will be marketing our story to investors on non-deal roadshows, and presenting at a number of investor conferences in New York, Las Vegas and Los Angeles, in the coming quarter. We see a number of near-term catalysts, such as our EU funded study in Europe, and we are all very much looking forward to the coming few months. We believe our upcoming efforts will further support our concept of the universal flu vaccine,” concluded Dr. Babecoff. PR Newswire
BVXV Technical Analysis
BVXV gapped up in price today to $5.46 up from yesterday’s close of $3.49 which is a 56% increase in price based on favorable news. Taking a look at the daily chart we have to go back to the 52 week highs on June 29 when the stock traded at $5.75 to find a price level above today’s open price. The stock is a biopharmaceutical company and they can be very volatile to news regarding their drug trials. The stock has a low float of 2.26 million shares and is trading on heavy volume making it a candidate for the gap and go strategy. The stock reached pre market highs of $5.93 which surpassed the stock’s previous 52 week high. The stock did give back $0.47 from the pre market highs to the open price, which could be a concern as the stock may be overextended at these levels. For trading purposes my entry point would be $5.60 looking for a run through $6 with a possible add on at pre market highs of $5.93. My stop loss would be $5.40 a little below the gap up price of $5.46, fearing anything below that and the stock will start to fill in the gap up.
Company Profile
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, develops universal influenza vaccine. Its lead product is the Multimeric-001 universal flu vaccine, which has completed two Phase II and two Phase I/II clinical trials to provide multi-season and multi-strain protection against human influenza virus strains, including seasonal and pandemic flu strains. The company was founded in 2003 and is based in Ness Ziona, Israel. Yahoo Finance
